PF-4708671

Licensed and Manufactured by Pfizer Catalog No.S2163

For research use only.

PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. PF-4708671 induces autophagy. First S6K1-specific inhibitor to be reported.

PF-4708671 Chemical Structure

CAS No. 1255517-76-0

Selleck's PF-4708671 has been cited by 41 publications

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Other S6 Kinase Products

Biological Activity

Description PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. PF-4708671 induces autophagy. First S6K1-specific inhibitor to be reported.
Targets
p70 S6K1 [1]
(Cell-free assay)
160 nM
In vitro

PF-4708671 is a piperazinyl-pyrimidine analogue and the first S6K1-specific inhibitor. PF-4708671 does not significantly inhibit the activity of the closely related S6K2 isoform or a number of other AGC kinases (Akt1, Akt2, PKA, PKCα, PKCϵ, PRK2, ROCK2, RSK1, RSK2 or SGK1) . PF-4708671 prevents the S6K1-mediated phosphorylation of S6 protein in response to IGF-1 (insulin-like growth factor 1), while having no effect upon the PMA-induced phosphorylation of substrates of the highly related RSK (p90 ribosomal S6 kinase) and MSK (mitogen- and stress-activated kinase) kinases. PF-4708671 is also found to induce phosphorylation of the T-loop and hydrophobic motif of S6K1, an effect that is dependent upon mTORC1 (mTOR complex 1). PF-4708671 does not affect activity of mTORC1. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BHT-101 NIewPG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwOEKwNlQh|ryP M{XYOHNCVkeHUh?=
UACC-893 M1nSemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkO5TWM2OD13LkG5PFg3KM7:TR?= MnHqV2FPT0WU
A427 M4ewZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTVwN{K1Olch|ryP M{nTXXNCVkeHUh?=
OCUB-M M{DYZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzSTWM2OD14Lk[2NVAzKM7:TR?= M4DlTnNCVkeHUh?=
SW684 M1vRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTdwNUKyOlgh|ryP MmXYV2FPT0WU
SK-LMS-1 Ml;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWS5OYhTUUN3ME25MlAyOzB{IN88US=> Mn\QV2FPT0WU
CP50-MEL-B MkDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPpSFlKSzVyPUmuN|A1OTlizszN MYXTRW5ITVJ?
NCI-H1651 M2XaVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HVOGlEPTB;MUCuNFI4PiEQvF2= NUHiR2JoW0GQR1XS
ABC-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTKTWM2OD1zMD6xNFM4KM7:TR?= MUfTRW5ITVJ?
OE19 M{XI[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlu3TWM2OD1zMD6xO|M{KM7:TR?= MmX2V2FPT0WU
DSH1 M3TYWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEn4cXBKSzVyPUGwMlg5PzlizszN MXfTRW5ITVJ?
SW13 MlrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jhd2lEPTB;MUGuPVMyQSEQvF2= NHnuTXdUSU6JRWK=
MDA-MB-453 MkHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTF{LkG2NFMh|ryP NIO1ZpBUSU6JRWK=
647-V MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWK2NJdrUUN3ME2xNk4{PTh{IN88US=> M2XkUXNCVkeHUh?=
NCI-H2342 NX\3PGV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moq2TWM2OD1zMj6zPVk2KM7:TR?= NGX2U5VUSU6JRWK=
LB2241-RCC MkLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXqTWM2OD1zMj61O|c6KM7:TR?= NWL6[otmW0GQR1XS
UACC-257 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTF|LkS0OVMh|ryP MVHTRW5ITVJ?
NCI-H661 Ml7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTF|Lk[0OFkh|ryP MknsV2FPT0WU
FADU M3HNe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYSyd3JiUUN3ME2xN{43QTl{IN88US=> MVfTRW5ITVJ?
A2780 M3;oVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33QO2lEPTB;MUOuPFA1OSEQvF2= NWXtVYFJW0GQR1XS
NCI-H1793 NVnad2ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTF2LkSwPFUh|ryP MmrxV2FPT0WU
TE-8 M2LUbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1naT2lEPTB;MUWuN|Q3PSEQvF2= MnzRV2FPT0WU
HGC-27 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mny0TWM2OD1zNj6xOlQ1KM7:TR?= NYHSXWZHW0GQR1XS
MMAC-SF M1LSfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXzbVdsUUN3ME2xO{4{PzJ5IN88US=> NVXGWWhMW0GQR1XS
Calu-6 NE\mR2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTF6LkG1NVMh|ryP Mn62V2FPT0WU
HUTU-80 NGnIZYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmmxTWM2OD1zOD6zPVU6KM7:TR?= NYTienRVW0GQR1XS
SAS MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;ITWM2OD1zOD62OFU2KM7:TR?= MnTjV2FPT0WU
IST-MES1 Ml\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLORoxsUUN3ME2xPE43PTB6IN88US=> NYLNU2x[W0GQR1XS
C3A MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF6xe2lKSzVyPUG4Mlc6OTlizszN Mn6xV2FPT0WU
ES3 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTF6LkizOlQh|ryP MXHTRW5ITVJ?
HSC-2 M3\kS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3n2RWlEPTB;MUmuOlU1OSEQvF2= NGjDe2tUSU6JRWK=
T47D MoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\ITWM2OD1{MD6xOFg2KM7:TR?= M1;xO3NCVkeHUh?=
EW-7 NEHaTXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIixWWlKSzVyPUKwMlg2QDhizszN NIS3bXZUSU6JRWK=
LN-405 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDOTWM2OD1{MD64PVY2KM7:TR?= M4nBT3NCVkeHUh?=
U031 NFvuZ|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWq1RWY5UUN3ME2yNU41QDB{IN88US=> MnrDV2FPT0WU
A549 NXrxT3FsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTJzLki0PVEh|ryP MYDTRW5ITVJ?
RMG-I M{HYN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzMTWM2OD1{Mj6yOlY5KM7:TR?= NWnV[WZJW0GQR1XS
BT-474 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfNTWM2OD1{Mj62OVUyKM7:TR?= NWr1VmlHW0GQR1XS
NB69 M37zSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvjdWxKSzVyPUKzMlE2OiEQvF2= NXXmV5cxW0GQR1XS
NB7 M{WzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\WdmlEPTB;MkSuNVg5KM7:TR?= MYjTRW5ITVJ?
HCC1569 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTJ2Lk[xNlUh|ryP MX\TRW5ITVJ?
MEL-JUSO M2j4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTJ2Lk[5NFgh|ryP NULP[lFIW0GQR1XS
MDA-MB-175-VII NG[wPVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfHc2lZUUN3ME2yOU4zPTF5IN88US=> NULHUmtbW0GQR1XS
HCC1419 NUiyZ|NtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknjTWM2OD1{NT62NFA{KM7:TR?= MmDTV2FPT0WU
Ca9-22 NF[4RWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljjTWM2OD1{NT62OFMzKM7:TR?= M2ryUXNCVkeHUh?=
KGN MkjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIezc2dKSzVyPUK1Mlc2PDdizszN M3TuOnNCVkeHUh?=
LB373-MEL-D NGS2WIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojHTWM2OD1{Nj6xPVM5KM7:TR?= MXrTRW5ITVJ?
NCI-H1755 NHLFSJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPtNJpPUUN3ME2yOk45QDRzIN88US=> NXHHXlJ6W0GQR1XS
D-423MG MmPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHH[HFKSzVyPUK3MlA4OTVizszN NHXaU|NUSU6JRWK=
DK-MG NUDOS|k6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\0TWM2OD1{OD63PFQ3KM7:TR?= M1njfHNCVkeHUh?=
NCI-H1623 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTJ6LkizOFIh|ryP MlTDV2FPT0WU
KU-19-19 Mk\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{OwSWlEPTB;MkiuPVk2KM7:TR?= NUfwWFE1W0GQR1XS
C-33-A M175Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{noNGlEPTB;MkmuNlE6QCEQvF2= MWDTRW5ITVJ?
SCC-4 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TGNGlEPTB;M{CuN|M2PCEQvF2= M2P3dXNCVkeHUh?=
MG-63 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnxSnVKSzVyPUOwMlU6QTRizszN NF7UeJpUSU6JRWK=
LNCaP-Clone-FGC NWnRZ3lrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fQTmlEPTB;M{GuOFkzOSEQvF2= NEGxdZdUSU6JRWK=
CAPAN-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXPTWM2OD1|MT61Nlg3KM7:TR?= NG\wVoRUSU6JRWK=
GI-ME-N NG\OcFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTNzLkWzOVMh|ryP M4ThXnNCVkeHUh?=
RERF-LC-MS M4ewSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPITWM2OD1|Mj62O|Q4KM7:TR?= M16wXnNCVkeHUh?=
KLE NXXjW4FYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrObpJ{UUN3ME2zN{41OzN2IN88US=> M2rE[XNCVkeHUh?=
KNS-81-FD NYjEOZNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjYTVJKSzVyPUOzMlUxODhizszN MXnTRW5ITVJ?
DOK NWq2UnBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1e1WWlEPTB;M{SuOlYyOiEQvF2= NVP2bndHW0GQR1XS
ACHN NVPub3VMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfMTWM2OD1|NT6xOVg5KM7:TR?= NX\4UFNMW0GQR1XS
KYSE-520 NVPLb4l6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULtbZZEUUN3ME2zOU4zOzZzIN88US=> MWDTRW5ITVJ?
SBC-5 NX;1bVBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlyyTWM2OD1|NT61NVE3KM7:TR?= M1PGeXNCVkeHUh?=
NCI-H28 MmPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPpSJNUUUN3ME2zOU43Pjl3IN88US=> M1rBcXNCVkeHUh?=
ES7 Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTN4LkKyOFkh|ryP M3z0bHNCVkeHUh?=
A172 Ml23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlr3TWM2OD1|Nj60NVg4KM7:TR?= NHnQVYJUSU6JRWK=
UM-UC-3 NWPhbY9nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3jSm9KSzVyPUO3Mlg4PDZizszN NFTBUJBUSU6JRWK=
LXF-289 MkSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjhfFRKSzVyPUO4MlAxPDdizszN M4G3OnNCVkeHUh?=
KP-4 NXf0TGhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmL3TWM2OD1|OD60O|M6KM7:TR?= NXPDRpFzW0GQR1XS
TE-1 NIjBfmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTN7Lk[1PFkh|ryP NXvaZYtGW0GQR1XS
G-402 NH62OWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTRyLkC2NUDPxE1? MVjTRW5ITVJ?
786-0 Mk\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTRyLkmwPVYh|ryP MoTOV2FPT0WU
K5 MlvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PuPWlEPTB;NEGuN|Y5PiEQvF2= NUfITYxRW0GQR1XS
SK-N-DZ M1fHd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DmRWlEPTB;NEGuN|gzOyEQvF2= NVnWO4l7W0GQR1XS
OVCAR-4 NV34WGRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1r4N2lEPTB;NEGuO|U3QCEQvF2= NI\qWpBUSU6JRWK=
T84 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;CdnhKSzVyPUSyMlEzPjNizszN NFjNPWZUSU6JRWK=
GCIY NIPqZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjybYRKSzVyPUSzMlA5ODNizszN NXSwZWhwW0GQR1XS
BB49-HNC NYW4XIROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml:0TWM2OD12Mz6zN|Q5KM7:TR?= MUnTRW5ITVJ?
SNU-C2B MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jyRmlEPTB;NEOuOlQ{PiEQvF2= M{HmXXNCVkeHUh?=
TE-6 MofTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTYTWM2OD12Mz64PFk1KM7:TR?= NH:xb45USU6JRWK=
23132-87 NX\IZoh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjHTWM2OD12ND6yPVc5KM7:TR?= M4DObXNCVkeHUh?=
DMS-53 NXXZWZBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTWd5NLUUN3ME20OE4{Ozh2IN88US=> MmTiV2FPT0WU
ONS-76 NF\BbIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\nTWM2OD12ND63OlYyKM7:TR?= MYjTRW5ITVJ?
DMS-273 NXK0fG9uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvsRWFbUUN3ME20OE46PDNizszN M2PCeHNCVkeHUh?=
COLO-824 M3HR[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTR3Lki3O|Uh|ryP NWCxVVlyW0GQR1XS
DMS-114 M1zZS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjhZ2hGUUN3ME20OU45QTJ5IN88US=> MnrNV2FPT0WU
YKG-1 NHrvVW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjNZ2x{UUN3ME20Ok4xOzV3IN88US=> NEjkR4hUSU6JRWK=
RH-18 MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTR4LkO3N|Mh|ryP NWO5R4FHW0GQR1XS
NCI-H1355 NGHYbY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33x[2lEPTB;NE[uOlE5KM7:TR?= MoG1V2FPT0WU
NCI-H2170 M2jIe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWX0U5dlUUN3ME20O{44PTh2IN88US=> NFq3N3pUSU6JRWK=
OC-314 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTVN2xKSzVyPUS3Mlg1PzhizszN MVTTRW5ITVJ?
NCI-H2030 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\xSWlEPTB;NEeuPFkxPiEQvF2= NYrkTWxkW0GQR1XS
22RV1 MkC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHKWVFKSzVyPUS3MlkxOTVizszN NEe5fJpUSU6JRWK=
G-401 NWPuO4hiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTR6LkS0NVUh|ryP MXPTRW5ITVJ?
YAPC NETGc4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HiZmlEPTB;NEmuPFA4OyEQvF2= M2nuUnNCVkeHUh?=
SW1573 NGHw[ohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDuTWM2OD13MD6yOFM2KM7:TR?= MWnTRW5ITVJ?
COLO-792 NXHWTI9iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XDdGlEPTB;NUCuOlI{PyEQvF2= NH3xS2RUSU6JRWK=
KNS-62 MmSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXoTWM2OD13MD63OVA5KM7:TR?= MlfzV2FPT0WU
NB5 M{fwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUm4dVJCUUN3ME21NU41PTB7IN88US=> NGfOUmRUSU6JRWK=
CP66-MEL M2DCXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTVzLk[0NFgh|ryP MlnIV2FPT0WU
CaR-1 M2fGdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HRbmlEPTB;NUKuNFYxPiEQvF2= NVvTN|BDW0GQR1XS
CAL-54 Mn35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTV{LkGxNFIh|ryP MnPyV2FPT0WU
8305C MlrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHOZYFKSzVyPUWyMlMyPSEQvF2= MWDTRW5ITVJ?
Calu-3 MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHTXXVKSzVyPUWyMlM4OzNizszN NFLOWoRUSU6JRWK=
AU565 NEnQPWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHaTWM2OD13Mj61OVA6KM7:TR?= MnvYV2FPT0WU
CW-2 NGLEW3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1O3PGlEPTB;NUKuPFY2PCEQvF2= MWnTRW5ITVJ?
BEN MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rDfGlEPTB;NUOuO|g3OiEQvF2= NH;OOnlUSU6JRWK=
NCI-H1975 MnP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYmx[WpsUUN3ME21N{45QTZ4IN88US=> MYDTRW5ITVJ?
HCT-116 NXTCZXpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmT1TWM2OD13ND6wN|I4KM7:TR?= MoG1V2FPT0WU
SH-4 NVfW[I1ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknyTWM2OD13ND6xN|gh|ryP MV7TRW5ITVJ?
NCI-H1693 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTV2LkKxNFMh|ryP M3fkVnNCVkeHUh?=
BPH-1 NUDSeFd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\XUJBKSzVyPUW1MlI5QTJizszN NGTiS2hUSU6JRWK=
CAMA-1 MoK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;6b|JKSzVyPUW1MlgyOTZizszN NUDQOmkzW0GQR1XS
A388 NXKzU5luT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTV4LkC5PFUh|ryP NH7EOXFUSU6JRWK=
C2BBe1 M{nPfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4i0SWlEPTB;NU[uNlY{PCEQvF2= MYHTRW5ITVJ?
GAMG NEDPfVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\uPG5KSzVyPUW2MlU6PTVizszN MmL4V2FPT0WU
MKN28 NHqyfHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17QdGlEPTB;NU[uPFAyOyEQvF2= NWiwTFZkW0GQR1XS
VA-ES-BJ MkHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fOPGlEPTB;NU[uPFc1PSEQvF2= NH;KW4pUSU6JRWK=
HuCCT1 MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXHfJFKSzVyPUW3MlA1QTJizszN M2nkS3NCVkeHUh?=
BFTC-905 NX7Cc41bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnLWW13UUN3ME21O{4zQDl6IN88US=> MlLxV2FPT0WU
LS-123 MmftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjoXXpqUUN3ME21O{42PjZ6IN88US=> MXvTRW5ITVJ?
LB996-RCC MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3RUoFKSzVyPUW4MlAzQDdizszN M2jTcHNCVkeHUh?=
NCI-H1048 NH\BdFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1yyOWlEPTB;NUiuNlE5QCEQvF2= NF;uSWpUSU6JRWK=
COR-L105 MnvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XuTGlEPTB;NUiuO|M{PyEQvF2= NV2yWpVvW0GQR1XS
OVCAR-8 Mmn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TX[GlEPTB;NUmuNVcyPiEQvF2= NY[yXXR4W0GQR1XS
SK-N-FI NY\PdXBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HocGlEPTB;NUmuN|IxPyEQvF2= NEDBcHNUSU6JRWK=
MES-SA NYnSWJJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXmSW5pUUN3ME21PU41PTB7IN88US=> M{LDR3NCVkeHUh?=
SCC-9 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTxUpE6UUN3ME21PU41PzV|IN88US=> MkmzV2FPT0WU
EFO-27 NXj4fmx3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVX5TJhEUUN3ME21PU46PDNizszN NV[wZmMxW0GQR1XS
GT3TKB NUC3bndWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TXdWlEPTB;NkCuOlA1QCEQvF2= MX7TRW5ITVJ?
HCC38 M4nFWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHMTWM2OD14MT60N|c6KM7:TR?= MmrQV2FPT0WU
MLMA M2HLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4r2XWlEPTB;NkGuOlE3OyEQvF2= NXzyVFlxW0GQR1XS
D-566MG NE\xWY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPkdZRKSzVyPU[zMlUzOjRizszN MWfTRW5ITVJ?
SF295 MkK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmr1TWM2OD14Mz62OlU2KM7:TR?= NXHmSXAzW0GQR1XS
ES4 M4Xkc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7wXnlQUUN3ME22OE41PzF7IN88US=> NF\C[YxUSU6JRWK=
CAKI-1 NV;GfWVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{G5e2lEPTB;NkSuOVczOSEQvF2= NVnIdVNlW0GQR1XS
OAW-28 NGnFTJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnneIFKSzVyPU[0Mlk3PDdizszN NYLXXYROW0GQR1XS
NCI-H460 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTZ3LkC4PVch|ryP M4LTeHNCVkeHUh?=
JAR NGXiW4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TjOmlEPTB;NkWuOVUyPiEQvF2= NITET41USU6JRWK=
SNU-449 NEfuNJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXlNZhKSzVyPU[1Mlc3OTZizszN NYPybIhXW0GQR1XS
D-392MG M4fScmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPz[pRQUUN3ME22OU46PDN2IN88US=> Mly1V2FPT0WU
EW-22 M33hVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvYTWM2OD14Nj6zPVUh|ryP MYnTRW5ITVJ?
GCT MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLRTWM2OD14Nz6wOFQ{KM7:TR?= M33IS3NCVkeHUh?=
NOS-1 NWfpb3g1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzMTllKSzVyPU[3MlY5PjdizszN NW\kTYJPW0GQR1XS
RH-1 M{Hme2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\U[2lEPTB;NkiuOVU2QSEQvF2= MmXjV2FPT0WU
HuH-7 NFXhdHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmizTWM2OD14OT6xNFAzKM7:TR?= NYXPe3UxW0GQR1XS
NUGC-3 M4LlTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTdyLkm2OFQh|ryP M{C3fXNCVkeHUh?=
IST-SL1 NX76U2RST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4npPGlEPTB;N{GuNlMzPCEQvF2= NELacFBUSU6JRWK=
SHP-77 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIK1eXVKSzVyPUeyMlEyQSEQvF2= M3fOVnNCVkeHUh?=
SW1116 M{Dpemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH20eXVKSzVyPUeyMlE1ODdizszN MVrTRW5ITVJ?
LK-2 M3GwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXNSYZ{UUN3ME23Nk45PjF{IN88US=> NVmzW|FzW0GQR1XS
U-2-OS MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTd|LkG4Nlgh|ryP NWDqNpA5W0GQR1XS
KYSE-150 M{j3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XiTGlEPTB;N{OuOlEyQCEQvF2= MXvTRW5ITVJ?
U251 M1PiV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:wTWM2OD15Mz64NVY5KM7:TR?= Mon1V2FPT0WU
HT-1080 NH:1d2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfBS5FKSzVyPUe0MlI2PzRizszN M1\NOnNCVkeHUh?=
NCI-H1437 MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXqOYNKSzVyPUe0MlY{OjZizszN NG\xcmJUSU6JRWK=
HPAF-II NXj3dXZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknwTWM2OD15ND62OFE2KM7:TR?= M4XrR3NCVkeHUh?=
Becker NE\yeGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2T1NWlEPTB;N{WuNVExPSEQvF2= M3j2e3NCVkeHUh?=
PANC-10-05 NWjVToRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX64eI1YUUN3ME23OU4zQDZ3IN88US=> NGjSR|NUSU6JRWK=
TYK-nu NESwdlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVG3XpRLUUN3ME23OU4{OTB{IN88US=> NYHSd|czW0GQR1XS
SKG-IIIa MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvRTWM2OD15NT6zN|QyKM7:TR?= M2fvcXNCVkeHUh?=
NCI-H1993 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXhbW5kUUN3ME23OU44Ozl5IN88US=> MmPFV2FPT0WU
S-117 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTPUZVTUUN3ME23OU44PTVizszN MoTEV2FPT0WU
HuO9 NFT2c5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LW[mlEPTB;N{[uNFA1QCEQvF2= M2i2VnNCVkeHUh?=
CAL-51 NEC1UXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX:wR2VuUUN3ME23Ok4yODB4IN88US=> MYnTRW5ITVJ?
BT-20 M4nqTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTd4LkKxOlgh|ryP NFrXVo5USU6JRWK=
LB831-BLC Ml\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjFdXNKSzVyPUe2MlMzOTdizszN MnfiV2FPT0WU
LB1047-RCC MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{O2dWlEPTB;N{[uO|YyQSEQvF2= MWjTRW5ITVJ?
ES8 NHn2fIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;BW5E{UUN3ME23PE4xODd|IN88US=> MVHTRW5ITVJ?
UMC-11 M2D0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mle5TWM2OD15OD6wPFg1KM7:TR?= NIHlNo5USU6JRWK=
NCI-H226 M33LcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jHRWlEPTB;N{iuNVMyPSEQvF2= M1;acnNCVkeHUh?=
IGROV-1 NUjNSXBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTd6LkW1OUDPxE1? NFPs[mxUSU6JRWK=
BHY NX\Yd4NpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml:wTWM2OD15OT61PVYh|ryP M1rHWXNCVkeHUh?=
MKN45 Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRThyLkOxO|Qh|ryP NE\yb4lUSU6JRWK=
IA-LM NGi0T2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoSyTWM2OD16MD6zOVEyKM7:TR?= NID1UXBUSU6JRWK=
WM-115 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzCTWM2OD16MT60NVE1KM7:TR?= NF;pVFlUSU6JRWK=
VMRC-RCZ MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRThzLkS0NlUh|ryP MVvTRW5ITVJ?
NCI-H2291 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX36PWZ2UUN3ME24NU43QDR{IN88US=> NVO1OGU2W0GQR1XS
MCF7 NYnCWllWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYOxe4ZHUUN3ME24N{4zQDl5IN88US=> MUTTRW5ITVJ?
639-V NWWyeYRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPpTWM2OD16ND62NVI6KM7:TR?= M1zp[3NCVkeHUh?=
RT4 MnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3ZTWM2OD16NT6yOFA{KM7:TR?= MonEV2FPT0WU
NCI-H2405 M1zIc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{[xRmlEPTB;OEWuNlk6PyEQvF2= NF7JUIpUSU6JRWK=
CAL-33 M{f5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmD2TWM2OD16NT62N|E2KM7:TR?= NHvqS|hUSU6JRWK=
BT-549 M{XzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHZbmtUUUN3ME24OU46Ozh{IN88US=> MUHTRW5ITVJ?
HT-1197 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLLeoVKSzVyPUi4MlExPzdizszN NEfneWhUSU6JRWK=
G-361 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HJ[GlEPTB;OEiuNVQ4PCEQvF2= NF3VToJUSU6JRWK=
LS-411N M{\4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2WzVGlEPTB;OEmuN|M5QCEQvF2= NFPyWXFUSU6JRWK=
HT-144 MmX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHsN2ZKSzVyPUi5MlU6QTJizszN NHT4fpJUSU6JRWK=
DJM-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjuPZNOUUN3ME24PU45QDR3IN88US=> NH23Z3JUSU6JRWK=
CAL-12T M4C5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3T2U2lEPTB;OUCuO|g6PSEQvF2= NHLIUolUSU6JRWK=
MKN7 NHfwbXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M331VmlEPTB;OUGuN|U2OSEQvF2= NGHzSIpUSU6JRWK=
HuP-T3 M3vzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWf4OGM5UUN3ME25Ok4yODB2IN88US=> M{O2cXNCVkeHUh?=
SK-MG-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTl4LkGzOFgh|ryP NV3Ke492W0GQR1XS
NCI-H2347 MmHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2q1T2lEPTB;OUiuNVA1OiEQvF2= MljnV2FPT0WU
SW872 NHz4VWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTFyMD60OVYh|ryP NETnfopUSU6JRWK=
COLO-829 MnziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXofFNKSzVyPUGwNE42PTNizszN Mlf3V2FPT0WU
MC-IXC M3TC[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHwTWM2OD1zMECuOlE2KM7:TR?= MXHTRW5ITVJ?
Assay
Methods Test Index PMID
Western blot p-mTOR / mTOR / p-p70S6K / p70S6K ; pS6 / S6 / pS6K / S6K1 / pAKT / AKT 30423811 28626016
Growth inhibition assay Cell viability 30423811

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 30 mg/mL
(76.84 mM)
Ethanol 8 mg/mL
(20.49 mM)
Water Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.

30 mg/mL

Chemical Information

Molecular Weight 390.41
Formula

C19H21F3N6

CAS No. 1255517-76-0
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCC1=CN=CN=C1N2CCN(CC2)CC3=NC4=C(N3)C=C(C=C4)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
Whether the in vivo formula "30% PEG400+0.5% Tween80+5% Propylene glycol" for S2163 is suitable for i.p. or not?

Answer:
The formula "30% PEG400+0.5% Tween80+5% Propylene glycol" on our website is an oral one. It is a suspension.

Tags: buy PF-4708671 | PF-4708671 supplier | purchase PF-4708671 | PF-4708671 cost | PF-4708671 manufacturer | order PF-4708671 | PF-4708671 distributor